| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2880293 | The Annals of Thoracic Surgery | 2009 | 8 Pages |
Abstract
Neoadjuvant trimodal treatment for histologically proven N2 or N3 stage III non-small cell lung cancer is promising and can, like no other approach at present time, considerably improve 5-year survival rates up to 63% in selected patients.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Volker MD, Thorsten MD, Bora MD, Tobias MD, Thomas MD, Stefanie MD, Jürgen PhD, Godehard MD,